Charles Schwab Investment Management Inc. Grows Stock Holdings in Haemonetics Co. (NYSE:HAE)

Charles Schwab Investment Management Inc. grew its holdings in shares of Haemonetics Co. (NYSE:HAE) by 1.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 551,193 shares of the medical instruments supplier’s stock after purchasing an additional 8,477 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.10% of Haemonetics worth $43,037,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Parkside Financial Bank & Trust raised its holdings in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the last quarter. KBC Group NV raised its holdings in Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Haemonetics in the 3rd quarter worth approximately $204,000. Versor Investments LP raised its holdings in Haemonetics by 9.1% in the 3rd quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 300 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in Haemonetics in the 4th quarter worth approximately $319,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on HAE shares. Needham & Company LLC decreased their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a report on Friday, February 7th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Trading Down 0.3 %

Shares of HAE stock opened at $65.76 on Friday. The firm has a fifty day moving average price of $68.61 and a 200-day moving average price of $75.42. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market cap of $3.30 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.